Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Trends in net survival from stomach cancer in six European Latin countries

results from the SUDCAN population-based study

Glória, Luísa; Bossard, Nadine; Bouvier, Anne-Marie; Mayer-da-Silva, Alexandra; Faivre, Jean; Miranda, Ana the GRELL EUROCARE-5 Working Group

European Journal of Cancer Prevention: January 2017 - Volume 26 - Issue - p S32–S39
doi: 10.1097/CEJ.0000000000000309
Supplement Articles

Gastric cancers are a clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from gastric cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and explore the trends in net survival and in the dynamics of the excess mortality rates (EMRs) up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000–2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These trend analyses were carried out using a flexible excess rate modelling strategy. There were little differences between countries in age-standardized net survival for stomach cancer (2000–2004). The 5-year net survival ranged between 26 (Spain) and 32% (Italy). There was a small increase in the age-standardized net survival at 1 year between 1992 and 2004. The increase was also observed in the 5-year net survival, except in France, where the increase was less marked. A slight decrease in the EMR between 1992 and 2004 was limited to the 24 months after diagnosis. In addition, the decrease in the EMR was the same whatever the year of diagnosis. There were minor differences in survival from stomach cancer between European Latin countries. A slight improvement in the 5-year net survival was observed in all countries and the major gain was observed during the 24 months after diagnosis. Development of innovative treatments is needed to improve the prognosis.

aDepartment of Epidemiology and South Regional Cancer Registry (ROR-Sul), Portuguese Institute of Oncology, Francisco Gentil, E.P.E, Lisbon, Portugal

bDepartment of Biostatistics, University Hospital of Lyon

cUniversity of Lyon, Lyon

dUniversity of Lyon 1

eCNRS, UMR 5558, Biometry and Evolutionary Biology Laboratory (LBBE), BioMaths-Health Department Villeurbanne

fDigestive Cancer Registry of Burgundy, INSERM U866, CHU Dijon, University of Burgundy, Dijon, France

* List of the members available at

Correspondence to Ana Miranda, MSc, Department of Epidemiology and South Regional Cancer Registry (ROR-Sul), Instituto Português de Oncologia de Lisboa, Francisco Gentil, E.P.E, Rua Professor Lima Basto, 1099-023 Lisbon, Portugal Tel: + 351 21 7229852; e-mail:

Received April 25, 2016

Accepted June 3, 2016

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.